Changeflow GovPing Healthcare & Life Sciences EP3814374A1 - Complement Alternative Pathway Ne...
Routine Rule Added Final

EP3814374A1 - Complement Alternative Pathway Nephropathy Biomarkers

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

Achillion Pharmaceuticals, Inc. has been granted European Patent EP3814374A1 for complement alternative pathway-associated nephropathy biomarkers. The patent, published April 15, 2026, names inventors Huang, Mingjun; Podos, Steven D.; Yang, Wengang; and Zhao, Yongsen, and covers multiple pharmaceutical compositions including C07K peptide classifications. The patent is designated across 31 European states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 46 changes logged to date.

What changed

The EPO has granted European Patent EP3814374A1 to Achillion Pharmaceuticals, Inc. covering complement alternative pathway-associated nephropathy biomarkers and related pharmaceutical compositions. The patent application, which was assigned IPC classifications including C07K 16/18, C07K 16/40, and multiple A61K therapeutic compositions, has proceeded to grant with A1 publication status.

Pharmaceutical and biotechnology companies active in complement pathway research or kidney disease therapeutics should review the patent's claims for potential freedom-to-operate concerns within the designated European contracting states. The granted claims may affect product development programmes targeting complement-mediated nephropathies in markets covered by the designation states including DE, FR, GB, IT, ES, and 26 other European jurisdictions.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

COMPLEMENT ALTERNATIVE PATHWAY-ASSOCIATED NEPHROPATHY BIOMARKERS

Publication EP3814374A1 Kind: A1 Apr 15, 2026

Applicants

Achillion Pharmaceuticals, Inc.

Inventors

HUANG, Mingjun, PODOS, Steven, D., YANG, Wengang, ZHAO, Yongsen

IPC Classifications

C07K 16/18 20060101AFI20220201BHEP C07K 16/40 20060101ALI20220201BHEP A61K 31/33 20060101ALI20220201BHEP A61K 31/395 20060101ALI20220201BHEP A61K 31/40 20060101ALI20220201BHEP A61K 31/41 20060101ALI20220201BHEP A61K 31/435 20060101ALI20220201BHEP A61K 39/395 20060101ALI20220201BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent grant Biotechnology research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!